344 related articles for article (PubMed ID: 18199809)
1. A neuronal microtubule-interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer's disease.
Matsuoka Y; Jouroukhin Y; Gray AJ; Ma L; Hirata-Fukae C; Li HF; Feng L; Lecanu L; Walker BR; Planel E; Arancio O; Gozes I; Aisen PS
J Pharmacol Exp Ther; 2008 Apr; 325(1):146-53. PubMed ID: 18199809
[TBL] [Abstract][Full Text] [Related]
2. A brain-penetrant triazolopyrimidine enhances microtubule-stability, reduces axonal dysfunction and decreases tau pathology in a mouse tauopathy model.
Zhang B; Yao Y; Cornec AS; Oukoloff K; James MJ; Koivula P; Trojanowski JQ; Smith AB; Lee VM; Ballatore C; Brunden KR
Mol Neurodegener; 2018 Nov; 13(1):59. PubMed ID: 30404654
[TBL] [Abstract][Full Text] [Related]
3. NAP protects memory, increases soluble tau and reduces tau hyperphosphorylation in a tauopathy model.
Shiryaev N; Jouroukhin Y; Giladi E; Polyzoidou E; Grigoriadis NC; Rosenmann H; Gozes I
Neurobiol Dis; 2009 May; 34(2):381-8. PubMed ID: 19264130
[TBL] [Abstract][Full Text] [Related]
4. NAP (davunetide) rescues neuronal dysfunction in a Drosophila model of tauopathy.
Quraishe S; Cowan CM; Mudher A
Mol Psychiatry; 2013 Jul; 18(7):834-42. PubMed ID: 23587881
[TBL] [Abstract][Full Text] [Related]
5. Disruption of neuronal function by soluble hyperphosphorylated tau in a Drosophila model of tauopathy.
Cowan CM; Chee F; Shepherd D; Mudher A
Biochem Soc Trans; 2010 Apr; 38(2):564-70. PubMed ID: 20298222
[TBL] [Abstract][Full Text] [Related]
6. High copy wildtype human 1N4R tau expression promotes early pathological tauopathy accompanied by cognitive deficits without progressive neurofibrillary degeneration.
Wheeler JM; McMillan PJ; Hawk M; Iba M; Robinson L; Xu GJ; Dombroski BA; Jeong D; Dichter MA; Juul H; Loomis E; Raskind M; Leverenz JB; Trojanowski JQ; Lee VM; Schellenberg GD; Kraemer BC
Acta Neuropathol Commun; 2015 Jun; 3():33. PubMed ID: 26041339
[TBL] [Abstract][Full Text] [Related]
7. NAP (davunetide) preferential interaction with dynamic 3-repeat Tau explains differential protection in selected tauopathies.
Ivashko-Pachima Y; Maor-Nof M; Gozes I
PLoS One; 2019; 14(3):e0213666. PubMed ID: 30865715
[TBL] [Abstract][Full Text] [Related]
8. Epothilone D improves microtubule density, axonal integrity, and cognition in a transgenic mouse model of tauopathy.
Brunden KR; Zhang B; Carroll J; Yao Y; Potuzak JS; Hogan AM; Iba M; James MJ; Xie SX; Ballatore C; Smith AB; Lee VM; Trojanowski JQ
J Neurosci; 2010 Oct; 30(41):13861-6. PubMed ID: 20943926
[TBL] [Abstract][Full Text] [Related]
9. The microtubule-stabilizing agent, epothilone D, reduces axonal dysfunction, neurotoxicity, cognitive deficits, and Alzheimer-like pathology in an interventional study with aged tau transgenic mice.
Zhang B; Carroll J; Trojanowski JQ; Yao Y; Iba M; Potuzak JS; Hogan AM; Xie SX; Ballatore C; Smith AB; Lee VM; Brunden KR
J Neurosci; 2012 Mar; 32(11):3601-11. PubMed ID: 22423084
[TBL] [Abstract][Full Text] [Related]
10. Novel tubulin and tau neuroprotective fragments sharing structural similarities with the drug candidate NAP (Davuentide).
Gozes I; Iram T; Maryanovsky E; Arviv C; Rozenberg L; Schirer Y; Giladi E; Furman-Assaf S
J Alzheimers Dis; 2014; 40 Suppl 1():S23-36. PubMed ID: 24503616
[TBL] [Abstract][Full Text] [Related]
11. Preventive methylene blue treatment preserves cognition in mice expressing full-length pro-aggregant human Tau.
Hochgräfe K; Sydow A; Matenia D; Cadinu D; Könen S; Petrova O; Pickhardt M; Goll P; Morellini F; Mandelkow E; Mandelkow EM
Acta Neuropathol Commun; 2015 May; 3():25. PubMed ID: 25958115
[TBL] [Abstract][Full Text] [Related]
12. A novel transgenic mouse expressing double mutant tau driven by its natural promoter exhibits tauopathy characteristics.
Rosenmann H; Grigoriadis N; Eldar-Levy H; Avital A; Rozenstein L; Touloumi O; Behar L; Ben-Hur T; Avraham Y; Berry E; Segal M; Ginzburg I; Abramsky O
Exp Neurol; 2008 Jul; 212(1):71-84. PubMed ID: 18490011
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of microtubule assembly competent tubulin synthesis leads to accumulation of phosphorylated tau in neuronal cell bodies.
Fujiwara H; Watanabe S; Iwata M; Ueda S; Nobuhara M; Wada-Kakuda S; Misonou H; Miyasaka T
Biochem Biophys Res Commun; 2020 Jan; 521(3):779-785. PubMed ID: 31699369
[TBL] [Abstract][Full Text] [Related]
14. Increased O-GlcNAcylation reduces pathological tau without affecting its normal phosphorylation in a mouse model of tauopathy.
Graham DL; Gray AJ; Joyce JA; Yu D; O'Moore J; Carlson GA; Shearman MS; Dellovade TL; Hering H
Neuropharmacology; 2014 Apr; 79():307-13. PubMed ID: 24326295
[TBL] [Abstract][Full Text] [Related]
15. Long-term treadmill exercise attenuates tau pathology in P301S tau transgenic mice.
Ohia-Nwoko O; Montazari S; Lau YS; Eriksen JL
Mol Neurodegener; 2014 Nov; 9():54. PubMed ID: 25432085
[TBL] [Abstract][Full Text] [Related]
16. Vaccination with Sarkosyl insoluble PHF-tau decrease neurofibrillary tangles formation in aged tau transgenic mouse model: a pilot study.
Ando K; Kabova A; Stygelbout V; Leroy K; Heraud C; Frédérick C; Suain V; Yilmaz Z; Authelet M; Dedecker R; Potier MC; Duyckaerts C; Brion JP
J Alzheimers Dis; 2014; 40 Suppl 1():S135-45. PubMed ID: 24614899
[TBL] [Abstract][Full Text] [Related]
17. Intranasal NAP administration reduces accumulation of amyloid peptide and tau hyperphosphorylation in a transgenic mouse model of Alzheimer's disease at early pathological stage.
Matsuoka Y; Gray AJ; Hirata-Fukae C; Minami SS; Waterhouse EG; Mattson MP; LaFerla FM; Gozes I; Aisen PS
J Mol Neurosci; 2007; 31(2):165-70. PubMed ID: 17478890
[TBL] [Abstract][Full Text] [Related]
18. Tau pathology in Alzheimer disease and other tauopathies.
Iqbal K; Alonso Adel C; Chen S; Chohan MO; El-Akkad E; Gong CX; Khatoon S; Li B; Liu F; Rahman A; Tanimukai H; Grundke-Iqbal I
Biochim Biophys Acta; 2005 Jan; 1739(2-3):198-210. PubMed ID: 15615638
[TBL] [Abstract][Full Text] [Related]
19. Enhancing microtubule stabilization rescues cognitive deficits and ameliorates pathological phenotype in an amyloidogenic Alzheimer's disease model.
Fernandez-Valenzuela JJ; Sanchez-Varo R; Muñoz-Castro C; De Castro V; Sanchez-Mejias E; Navarro V; Jimenez S; Nuñez-Diaz C; Gomez-Arboledas A; Moreno-Gonzalez I; Vizuete M; Davila JC; Vitorica J; Gutierrez A
Sci Rep; 2020 Sep; 10(1):14776. PubMed ID: 32901091
[TBL] [Abstract][Full Text] [Related]
20. Characterization of Brain-Penetrant Pyrimidine-Containing Molecules with Differential Microtubule-Stabilizing Activities Developed as Potential Therapeutic Agents for Alzheimer's Disease and Related Tauopathies.
Kovalevich J; Cornec AS; Yao Y; James M; Crowe A; Lee VM; Trojanowski JQ; Smith AB; Ballatore C; Brunden KR
J Pharmacol Exp Ther; 2016 May; 357(2):432-50. PubMed ID: 26980057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
